SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 04 2024
0mins
Source: TipRanks
Biotechnology Sector Overview:
- Biotech sector known for high risks but appealing long-term prospects.
- Companies focus on R&D for medical needs and tech advancements.
Investing in BioTech ETFs:
- Suitable for less savvy investors to diversify risks.
- Considered a defensive play against economic challenges.
Comparison of BioTech ETFs:
- Used TipRanks' tool to compare SBIO, XBI, and BBP.
- Ratings and targets based on consolidated stock data in each fund.
Specific BioTech ETF Details:
- SBIO: Strong Buy consensus, $65.62 price target.
- XBI: Strong Buy consensus, $158.37 price target.
- BBP: Strong Buy consensus, $99.71 price target.
Future Outlook:
- Analysts favor SBIO for significant upside potential.
- SBIO focuses on clinical-stage biotech companies with growth potential.
Analyst Views on BBP
Wall Street analysts forecast BBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 83.852
Low
Averages
High
Current: 83.852
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
